Skip to main content

STXS

Stock
Health Care
Medical Instruments & Supplies

Performance overview

STXS Price
Price Chart

Forward-looking statistics

Beta
0.91
Risk
65.23%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees152
Market cap$158.7M

Fundamentals

Enterprise value$182.9M
Revenue$27.5M
Revenue per employee—
Profit margin-92.19%
Debt to equity71.77

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$0.31
Dividend per share—
Revenue per share$0.32
Avg trading volume (30 day)$577K
Avg trading volume (10 day)$767K
Put-call ratio—

Macro factor sensitivity

Growth+3.4
Credit+3.7
Liquidity-1.4
Inflation+1.2
Commodities-0.3
Interest Rates-4.3

Valuation

Dividend yield0.00%
PEG Ratio-12.22
Price to sales6.88
P/E Ratio-12.22
Enterprise Value to Revenue6.65
Price to book66.67

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial

STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.

Zacks Investment Research (July 7, 2025)
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.

Zacks Investment Research (May 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free